| Document |
Document Title |
|
WO/2022/127825A1 |
The present application relates to a novel coronavirus pathogen-like antigen (PLA) vaccine, a preparation method therefor and an application thereof. The PLA vaccine consists of structurally-modified Escherichia coli virus-like particles...
|
|
WO/2022/129526A1 |
The invention relates to a compound comprising a GLP-1 receptor agonist and an amylin receptor agonist. The invention also relates to a pharmaceutical formulation, suitable for but not limited to oral administration, which comprises such...
|
|
WO/2022/121322A1 |
Disclosed is a fusion protein containing an antigen epitope of a novel coronavirus COVID-19 vaccine. The fusion protein consists of an antigen epitope fragment of the novel coronavirus COVID-19 vaccine and an immunoglobulin Fc fragment, ...
|
|
WO/2022/125901A1 |
This document provides methods and materials involved in treating cancer. For example, methods and materials for using T cells (e.g., chimeric antigen receptor (CAR) T cells) and one or more antigenic compositions (e.g., one or more comp...
|
|
WO/2022/125788A1 |
Provided herein are improved formulations of tagraxofusp for lyophilization used to manufacture stable formulations of tagraxofusp for intravenous injection.
|
|
WO/2022/125387A1 |
Disclosed herein is a polynucleotide comprising a human codon-optimized sequence encoding a polypeptide comprising EGFR806CAR. The codon-optimized sequence may be incorporated into a construct comprising an optimal-functioning promoter, ...
|
|
WO/2022/121239A1 |
The present invention provides a bispecific antibody and an application thereof. IL15 and IL15Rα are respectively introduced into two chains of a first antibody of the bispecific antibody of the present invention (for example, IL15 and ...
|
|
WO/2022/121118A1 |
Provided is a humanized anti-IL-4Rα single domain antibody. The antibody has a complementarity determining region and a humanized and modified framework region, the affinity and a tumor cell proliferation blocking effect are maintained,...
|
|
WO/2022/120942A1 |
Provided are a CLL1-targeting chimeric antigen receptor and an application thereof. The CLL1-targeting chimeric antigen receptor comprises an antigen-binding domain, a hinge region, a transmembrane domain, and a signaling domain, the ant...
|
|
WO/2022/122036A1 |
Disclosed in the present application are an immunogen and a pharmaceutical composition for SARS-CoV-2 virus, and the use thereof. The immunogen comprises at least one of a PreS protein or a full-length S protein, or the immunogen compris...
|
|
WO/2022/121899A1 |
Disclosed is an antibody specifically binding to a Strep-Tag II tag, and further disclosed are an amino acid sequence of the antibody of the present invention, a cloning or expression vector, a host cell, and a method for expressing or s...
|
|
WO/2022/121880A1 |
The present invention provides a CD19-targeting humanized antibody, and a multispecific antibody, chimeric receptor, antibody conjugate, pharmaceutical composition, and kit comprising the CD19-targeting humanized antibody, and a use ther...
|
|
WO/2022/124282A1 |
The present invention addresses the problem of providing a PRAME binding molecule. Said problem is solved by a PRAME binding molecule including: a heavy chain variable region that includes a heavy chain CDR1 having an amino acid sequence...
|
|
WO/2022/120908A1 |
A self-assembled nanoparticle containing a gB protein of an EB virus, and a preparation method therefor and the use thereof. The self-assembled nanoparticle comprises a first polypeptide and a second polypeptide. The first polypeptide co...
|
|
WO/2022/115951A1 |
Disclosed herein are methods for treating a neurodegenerative disease and/or an optic nerve, brain and/or spinal cord injury using a Ndfip1 fusion polypeptide, a Ndfip1 nucleic acid molecule, a construct or expression cassette comprising...
|
|
WO/2022/116086A1 |
Provided herein is a method of treating a subject who has multiple myeloma. A single infusion of chimeric antigen receptor (CAR) -T cells comprising an anti-BCMA CAR comprising a polypeptide is administered to the subject. The dose of CA...
|
|
WO/2022/117032A1 |
Provided are an CD22 nano antibody, and a preparation method therefor and an application thereof. The CD22 nano antibody has high affinity with a CD22 protein, and can be used for preparing drugs for treating tumors, autoimmune diseases,...
|
|
WO/2022/120383A1 |
The composition includes a first construct having a first portion of a protein and a first antigen-recognizing amino acid sequence; and a second construct having a second portion of the protein that catalyzes a reaction when combined wit...
|
|
WO/2022/115946A1 |
The present disclosure concerns the reduction in the immunosuppression and the increase in the anti-tumor immune cytotoxicity in a tissue by using an antagonist of the type 1 insulin growth factor receptor (IGF-1R). The present disclosur...
|
|
WO/2022/119923A1 |
The present disclosure provides BCMA-targeted chimeric antigen receptors (CARs) as well as preparation methods and applications thereof. The CARs of the present disclosure targets BCMA-positive cells, and can be used for treating BCMA-po...
|
|
WO/2022/116528A1 |
The present disclosure belongs to the technical fields of molecular biology and bioengineering, and relates to a circular RNA, a vaccine containing the circular RNA, and a kit for detecting a novel coronavirus neutralizing antibody. A re...
|
|
WO/2022/116952A1 |
An antigen-binding protein targeting CD70. In particular, the present invention relates to a chimeric antigen receptor containing the antigen binding protein and the use thereof, and cells containing or expressing the antigen binding pro...
|
|
WO/2022/116480A1 |
Provided are a trifunctional fusion protein containing a tumor-associated antigen (TAA) antibody, a TGF-β inhibitor, and a CD3 antibody, and an application thereof. By introducing a TGF-β inhibitor into antibody molecules, the trifunct...
|
|
WO/2022/110499A1 |
Disclosed are an application of a signal peptide in the expression of GLP-1 or a GLP-1 fusion protein. The amino acid sequence of the signal peptide is shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4. The signal peptide can...
|
|
WO/2022/109743A1 |
A fusion protein comprises a nanocage monomer or a subunit thereof linked to a DR4 and/or DR5 antigen-binding moiety, wherein a plurality of the fusion proteins self-assemble to form a nanocage. Also described is a nanocage comprising th...
|
|
WO/2022/111562A1 |
The present application relates to a fusion protein, and in particular to a modified immune cell containing the fusion protein and the use thereof. The fusion protein contains an antigen or a functionally active fragment thereof, a co-st...
|
|
WO/2022/110099A1 |
This disclosure relates to coronavirus vaccines and uses thereof. In one aspect, the disclosure provides a nucleic acid vaccine, comprising a sequence encoding a spike protein or fragment thereof derived from a coronavirus.
|
|
WO/2022/113075A1 |
Chimeric polypeptides comprising a first subunit comprising an antigen-binding domain, a second subunit comprising at least one immunogenic peptide comprising a signal peptide and a third subunit comprising a cleavable moiety, wherein th...
|
|
WO/2022/115864A1 |
Compositions and methods for treating diseases associated with expression of cluster differentiation 33 (CD33) and/or cluster differentiation 5 (CDS) are described. The compositions and methods relate to two chimeric antigen receptors (C...
|
|
WO/2022/111405A1 |
Provided in the present invention are an antibody targeting Claudin18.2, and a multispecific antibody, a chimeric antigen receptor, an antibody conjugate, a pharmaceutical composition and a kit comprising same, and the use thereof in the...
|
|
WO/2022/109023A1 |
This disclosure provides methods of treating cancer comprising administering effector cell engaging molecules comprising one or more tumor targeting moieties and one or more effector cell engaging moieties. For example, the effector cell...
|
|
WO/2022/105826A1 |
Provided are an NKG2A-targeting antibody, and a multispecific antibody, a chimeric receptor, an antibody conjugate, a pharmaceutical composition and a kit which comprise same, and the use thereof in the diagnosis/treatment/prevention of ...
|
|
WO/2022/105811A1 |
Provided are a humanized CD19 antibody and the use thereof. Specifically, provided are an antibody- or antigen-binding fragment capable of binding to CD19, a multi-specific antigen binding molecule, a chimeric antigen receptor, an immune...
|
|
WO/2022/105880A1 |
A fusion gene, a recombinant novel coronavirus high-efficiency immune DNA vaccine, a construction method therefor and use thereof. The immune DNA vaccine ZD-nCor19 provided therein uses RBD protein, segment 301-538aa of the S2 subunit an...
|
|
WO/2022/105847A1 |
Provided are long-acting nerve growth factor (NGF) polypeptides comprising from N-terminus to C-terminus an NGF moiety and an Fc moiety, methods of making, and uses thereof.
|
|
WO/2022/105751A1 |
A new fusion protein including a PD-L1 antibody and a TGFβ receptor, a nucleic acid encoding the fusion protein or a fragment thereof, a host cell comprising same, and the relevant use. In addition, the present invention also relates to...
|
|
WO/2022/109399A1 |
The present disclosure provides Transforming Growth Factor Beta (TGF-β) polypeptide constructs and complexes that find use in, for example, therapeutic treatment of diseases including autoimmune diseases and metabolic diseases and disor...
|
|
WO/2022/109220A1 |
The present disclosure provides for methods, systems, and compositions of nucleic acid and peptide sequences. The present disclosure provides for a nucleic acid sequence encoding at least two amino acid sequences selected from the group ...
|
|
WO/2022/105190A1 |
Provided are an adenosine deaminase and a related biomaterial and application thereof. The adenosine deaminase is a protein having an amino acid sequence represented by positions 1-167 of a sequence 2 in a sequence list and is called Tad...
|
|
WO/2022/105879A1 |
Isolated anti-human B7-H3 antibody includes two heavy chains including a hinge region comprising an amino acid sequence that allows site-specific conjugation of cytotoxic drugs. Each heavy chain includes a human CH1 domain located upstre...
|
|
WO/2022/100303A1 |
The present application relates to a kit and method for detecting a SARS-CoV-2 neutralizing antibody. The present application relates to the field of biological medicine, and provided are a kit and method for detecting a SARS-CoV-2 neutr...
|
|
WO/2022/101463A1 |
Apoptosis is the main mechanism by which Mosquito-borne Zika virus infection causes cell death. Here, the inventors aimed to determine whether the last C-terminal residues M31/41 of ZIKV M ectodomain can trigger apoptotic cell death. Apo...
|
|
WO/2022/101907A1 |
Provided herein are conjugates of retrograde tracers and cell-deactivating agents useful in targeting the nerve cells' body (soma) of neurons that are associated with pain, spasm or tonus, as well as methods of controllable selective dea...
|
|
WO/2022/100555A1 |
Provided are CD164 mucin domain fusion proteins with a heterologous protein, such as a heterologous protein with a therapeutic function and can benefit from extended serum half-life. Methods of using the fusion proteins are also provided.
|
|
WO/2022/099695A1 |
Provided are CD164 mucin domain fusion proteins with a heterologous protein, such as a heterologous protein with a therapeutic function and can benefit from extended serum half-life. Methods of using the fusion proteins are also provided.
|
|
WO/2022/100585A1 |
Provided are an anti-Her-2 antibody-chemokine fusion protein, a preparation method therefor and an application thereof. Specifically, provided is a fusion protein, the fusion protein comprising an anti-Her-2 antibody or an active fragmen...
|
|
WO/2022/100741A1 |
Provided is a fusion protein of human serum albumin or a wild type thereof and human interleukin-2 or a mutation thereof, said fusion protein has a significantly extended in vivo half-life relative to recombinant interleukin-2, can be us...
|
|
WO/2022/099963A1 |
Provided by the present invention are a fusion protein for improving the oral administration stability of a polypeptide drug, and an application thereof. The fusion protein of the present invention contains β-mannanase, a linker peptide...
|
|
WO/2022/095916A1 |
The present invention relates to the field of biotechnologies, and in particular, to a cell surface macromolecular quantitative display system, a preparation method therefor and use thereof. The cell surface macromolecular quantitative d...
|
|
WO/2022/095803A1 |
The present invention provides a CD7-targeting humanized antibody, and a multispecific antibody, chimeric antigen receptor, antibody conjugate, pharmaceutical composition, and kit comprising the CD7-targeting humanized antibody, and a us...
|
